Emerging Role of PD-1 in the Central Nervous System and Brain Diseases
10.1007/s12264-021-00683-y
- Author:
Junli ZHAO
1
;
Alexus ROBERTS
1
;
Zilong WANG
1
;
Ru-Rong JI
1
;
Alexus ROBERTS
2
;
Justin SAVAGE
3
;
Ru-Rong JI
3
;
Ru-Rong JI
4
Author Information
1. Department of Anesthesiology, Duke University Medical Center
2. Department of Biology, Duke University Medical Center
3. Department of Neurobiology, Duke University Medical Center
4. Department of Cell Biology, Duke University Medical Center
- Publication Type:Journal Article
- Keywords:
Central nervous system;
Immune checkpoint;
Immunotherapy;
Neurotherapy;
PD-1
- From:
Neuroscience Bulletin
2021;37(8):1188-1202
- CountryChina
- Language:Chinese
-
Abstract:
Programmed cell death protein 1 (PD-1) is an immune checkpoint modulator and a major target of immunotherapy as anti-PD-1 monoclonal antibodies have demonstrated remarkable efficacy in cancer treatment. Accumulating evidence suggests an important role of PD-1 in the central nervous system (CNS). PD-1 has been implicated in CNS disorders such as brain tumors, Alzheimer’s disease, ischemic stroke, spinal cord injury, multiple sclerosis, cognitive function, and pain. PD-1 signaling suppresses the CNS immune response via resident microglia and infiltrating peripheral immune cells. Notably, PD-1 is also widely expressed in neurons and suppresses neuronal activity via downstream Src homology 2 domain-containing protein tyrosine phosphatase 1 and modulation of ion channel function. An improved understanding of PD-1 signaling in the cross-talk between glial cells, neurons, and peripheral immune cells in the CNS will shed light on immunomodulation, neuromodulation, and novel strategies for treating brain diseases.
